<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">IBUTILIDE FUMARATE</span><br/>(i-bu'ti-lide)<br/><span class="topboxtradename">Corvert<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">antiarrhythmic agent, class iii</span><br/><b>Prototype: </b>Amiodarone HCl<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.1 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Ibutilide is a Class III antiarrhythmic agent. It prolongs the cardiac action potential and increases both atrial and ventricular
         refractoriness without effecting conduction (i.e., Class III antiarrhythmic electrophysiologic effects).
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>It is used to treat recently occurring atrial arrhythmias. Like other Class III antiarrhythmic drugs it may produce proarrhythmic
         effects that can be life threatening.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Rapid conversion of atrial fibrillation or atrial flutter of recent onset.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to ibutilide, pregnancy (category C), hypokalemia, hypomagnesia.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>History of CHF, ejection fraction of 35% or less, recent MI, prolonged QT intervals, liver disease, cardiovascular disorder
         other than atrial arrhythmias, other drugs that prolong QT interval, lactation. Safety and effectiveness in children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Atrial Fibrillation or Flutter</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span>
<i> 0.01 mg/kg (0.1 mL/kg), may repeat in 10  min if inadequate response; <img src="../images/special/greaterorequal.gif"/><i>60 kg,</i> 1 mg (10 mL), may repeat in 10 min if inadequate response<br/></i></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<ul>
<li>Hypokalemia and hypomagnesemia should be corrected prior to treatment with ibutilide.</li>
<li>Class Ia and other class III antiarrhythmic drugs should not be given concurrently or within 4 h of ibutilide.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Give undiluted.  <span class="methodtype">IV Infusion:</span> Contents of 1 mg vial may be diluted in 50 mL of D5W or NS to yield 0.017 mg/mL.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct/</span><span class="methodtype">IV Infusion:</span>  Give a single dose by direct injection or infusion over 10 min. Stop injection/infusion as soon as presenting arrhythmia is terminated or with appearance of ventricular tachycardia or marked
                  prolongation of QT or QT<sub>c</sub>. 
               </p>
</td>
</tr>
</table>
<ul>
<li>Store diluted solution up to 24 h at 15°30° C (59°86° F) or 48 h refrigerated at 2°8°
            C (36°46° F).
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache. <span class="typehead">CV:</span> Proarrhythmic effects (sustained and nonsustained polymorphic ventricular tachycardia), AV block, bundle branch block, ventricular
      extrasystoles, hypotension, postural hypotension, bradycardia, tachycardia, palpitations, prolonged QT segment. <span class="typehead">GI:</span> Nausea. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Increased potential for proarrhythmic effects when administered with <span class="classification">phenothiazines</span>, <span class="classification">tricyclic antidepressants</span>, <b>amiodarone,</b>
<b>disopyramide,</b>
<b>quinidine,</b>
<b>procainamide,</b>
<b>sotalol</b> may cause prolonged refractoriness if given within 4 h of ibutilide. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead"> Onset:</span>  30 min. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> 82% excreted in urine, 19% in feces. <span class="typehead">Half-Life:</span> 6 h (range 221 h). 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for therapeutic effectiveness. Conversion to normal sinus rhythm normally occurs within 30 min of initiation of infusion.</li>
<li>Observe with continuous ECG, BP, and HR monitoring during and for at least 4 h after infusion or until QT<sub>c</sub> has returned to baseline. Monitor for longer periods with liver dysfunction or if proarrhythmic activity is observed.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Consult physician and understand the potential risks of ibutilide therapy.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>